Targeted small molecule therapy and inhibitors for lymphoma

被引：0
作者：
Wang, Zhong-Hui [1 ]
Zheng, Xiang [1 ]
Rao, Guo-Wu [1 ]
Zheng, Quan [2 ]
机构：
[1] Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310014, Peoples R China
[2] Wenzhou Med Univ, Quzhou Affiliated Hosp, Quzhou Peoples Hosp, Core Facil, Quzhou 324000, Peoples R China
来源：
FUTURE MEDICINAL CHEMISTRY | 2024年 / 16卷 / 14期
关键词：
BTK; HDAC; inhibitor; lymphoma; PI3K delta; treatment; tumor; HISTONE DEACETYLASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; T-CELL LYMPHOMA; OPEN-LABEL; PHASE-II; ACALABRUTINIB ACP-196; FOLLICULAR LYMPHOMA; SINGLE-AGENT; PANOBINOSTAT; IBRUTINIB;
D O I：
10.1080/17568919.2024.2359893
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Lymphoma, a blood tumor, has become the ninth most common cancer in the world in 2020. Targeted inhibition is one of the important treatments for lymphoma. At present, there are many kinds of targeted drugs for the treatment of lymphoma. Studies have shown that Histone deacetylase, Bruton's tyrosine kinase and phosphoinositide 3-kinase all play an important role in the occurrence and development of tumors and become important and promising inhibitory targets. This article mainly expounds the important role of these target protein in tumors, and introduces the mechanism of action, structure-activity relationship and clinical research of listed small molecule inhibitors of these targets, hoping to provide new ideas for the treatment of lymphoma.
引用
收藏
页码：1465 / 1484
页数：20
相关论文
共 115 条
  • [11] Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
    Byrd, John C.
    Harrington, Bonnie
    O'Brien, Susan
    Jones, Jeffrey A.
    Schuh, Anna
    Devereux, Steve
    Chaves, Jorge
    Wierda, William G.
    Awan, Farrukh T.
    Brown, Jennifer R.
    Hillmen, Peter
    Stephens, Deborah M.
    Ghia, Paolo
    Barrientos, Jacqueline C.
    Pagel, John M.
    Woyach, Jennifer
    Johnson, Dave
    Huang, Jane
    Wang, Xiaolin
    Kaptein, Allard
    Lannutti, Brian J.
    Covey, Todd
    Fardis, Maria
    McGreivy, Jesse
    Hamdy, Ahmed
    Rothbaum, Wayne
    Izumi, Raquel
    Diacovo, Thomas G.
    Johnson, Amy J.
    Furman, Richard R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) : 323 - 332
  • [12] Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy
    Cao, Han-Yu
    Li, Ling
    Xue, Sheng-Li
    Dai, Hai-Ping
    [J]. HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 301 - 309
  • [13] Cao J., 2023, HEMATOL ONCOL, V41, P13, DOI [10.1002/hon.3165653, DOI 10.1002/HON.3165653]
  • [14] Synthesis and evaluation of sulfonamide derivatives targeting EGFR790M/L858R mutations and ALK rearrangement as anticancer agents
    Cao, Longcai
    Yao, Han
    Yu, Linlin
    Ren, Yuanyuan
    Liu, Jiadai
    Li, Xingshu
    Jia, Xian
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2023, 85
  • [15] Idelalisib in the management of lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    [J]. BLOOD, 2016, 128 (03) : 331 - 336
  • [16] 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment
    Chen, Yadong
    Li, Huifang
    Tang, Wanquan
    Zhu, Chengchao
    Jiang, Yongjun
    Zou, Jianwei
    Yu, Qingsen
    You, Qidong
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (07) : 2868 - 2876
  • [17] Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat
    Cheng, Tiewei
    Kiser, Kendall
    Grasse, Leslie
    Iles, Lakesla
    Bartholomeusz, Geoffrey
    Samaniego, Felipe
    Orlowski, Robert Z.
    Chandra, Joya
    [J]. CANCER DRUG RESISTANCE, 2021, 4 (04) : 888 - 902
  • [18] Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth
    Cisse, Ouma
    Quraishi, Muzthahid
    Gulluni, Federico
    Guffanti, Federica
    Mavrommati, Ioanna
    Suthanthirakumaran, Methushaa
    Oh, Lara C. R.
    Schlatter, Jessica N.
    Sarvananthan, Ambisha
    Broggini, Massimo
    Hirsch, Emilio
    Falasca, Marco
    Maffucci, Tania
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
  • [19] CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target
    Cuesta-Mateos, Carlos
    Terron, Fernando
    Herling, Marco
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [20] Orelabrutinib: First Approval
    Dhillon, Sohita
    [J]. DRUGS, 2021, 81 (04) : 503 - 507
12345678910